Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

Rhea-AI Summary

Gamida Cell Ltd. (NASDAQ: GMDA) will host a conference call on August 15, 2022, at 8:00 a.m. ET to discuss its second quarter 2022 financial results. The call will provide updates on the company's ongoing developments, including its innovative cell therapy pipeline targeting hematologic and solid cancers. Gamida Cell continues to advance its proprietary NAM-enabled therapies, including omidubicel, which aims to improve outcomes for patients needing bone marrow transplants. A live audio webcast will be available, with a replay accessible for 30 days.

Positive

• Upcoming conference call to review Q2 2022 results and company update enhances investor engagement.
• Focus on innovative therapies, including omidubicel, indicating potential for strong market impact.

Negative

• None.

BOSTON--(BUSINESS WIRE)-- Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious diseases, today announced that the company will host a conference call and live audio webcast on Monday, August 15, 2022, at 8:00 a.m. ET to review its second quarter 2022 financial results and provide an update on the company.

To access the conference call, please register here and be advised to do so at least 10 minutes prior to joining the call. A live webcast of the conference call can be accessed in the “Investors & Media” section of Gamida Cell’s website at www.gamida-cell.com. A replay of the webcast will be available approximately two hours after the event, for approximately 30 days.

About Gamida Cell

Gamida Cell is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumor and blood cancers and other serious blood diseases. We apply a proprietary expansion platform leveraging the properties of NAM to allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapy candidates with potential to redefine standards of care. These include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant, and a line of modified and unmodified NAM-enabled NK cells targeted at solid tumor and hematological malignancies. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn, Twitter, Facebook or Instagram at @GamidaCellTx.

Cautionary Note Regarding Forward Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to timing of initiation and progress of, and data reported from, the clinical trials of Gamida Cell’s product candidates (including omidubicel and GDA-201), anticipated regulatory filings (including the timing of review of the BLA for omidubicel to the FDA), commercialization planning efforts, and the potentially life-saving or curative therapeutic and commercial potential of omidubicel, and Gamida Cell’s expectations for the expected clinical development milestones set forth herein. Any statement describing Gamida Cell’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on our business, and including the scope, progress and expansion of Gamida Cell’s clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of developing and commercializing product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Gamida Cell’s Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (SEC) on May 12, 2022, and other filings that Gamida Cell makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Gamida Cell’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Gamida Cell’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Gamida Cell. As a result, you are cautioned not to rely on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220808005340/en/

For investors:

Courtney Turiano

Stern Investor Relations, Inc.

courtney.turiano@sternir.com

1-212-362-1200

For media:

Heather DiVecchia

Chief of Staff

Heather@gamida-cell.com

1-617-892-9083

Source: Gamida Cell Ltd.

FAQ

When will Gamida Cell announce its Q2 2022 financial results?

Gamida Cell will announce its Q2 2022 financial results on August 15, 2022.

What is the focus of Gamida Cell's upcoming conference call?

The focus will be on reviewing the second quarter 2022 financial results and providing company updates.

How can I access the Gamida Cell conference call?

The conference call can be accessed by registering on their website or through a provided link in the press release.

What therapies is Gamida Cell currently developing?

Gamida Cell is developing NAM-enabled cell therapies, including omidubicel for bone marrow transplants and NK cell therapies for solid tumors.